Form 8-K · Current Report · Filed 2026-09-01
Revolution Medicines, Inc. Announces Lease Agreement for New Headquarters
Revolution Medicines, Inc. has entered into a material definitive agreement to lease four buildings in Redwood City, California, totaling approximately 672,000 rentable square feet, as its new headquarters. The lease agreements, structured with four separate landlords, have staggered commencement dates starting September 26, 2027, and extend through September 1, 2028, with initial terms ending in September 2042. The Company has options to extend the leases for up to three additional five-year periods. The lease includes rent-abatement periods extending through January 2030, with an aggregate base rent abatement of approximately $23.1 million. The landlords have agreed to provide aggregate tenant improvement allowances of approximately $115.9 million, with an option for the Company to receive up to an additional $40.3 million. The effectiveness of the leases is contingent upon the acquisition of the properties by the landlords, with specific conditions and potential rent reductions based on the timing of the acquisition.
- Filer
- Revolution Medicines Inc. RVMD · NASDAQ
- Filed
- Accession
- 0001193125-26-377362
- CIK
- 0001628171
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$205.57
Since filing
+0.0%
Latest close
$205.57
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVMD reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, RVMD insiders reported 30 Form 4 transactions — net selling of $28.4M.
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Never miss another RVMD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.